COVID-19 vaccine protection fades within months due to a lack of long-lived plasma cells. Booster shots restore some immunity ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

The Food and Drug Administration (FDA) will require more evidence for what top officials describe as the uniquely American ...

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

Under the new FDA guidelines, only people 65 and older and others with one or more health risk factors will be able to receive COVID-19 vaccinations. People considered healthy and under the age of 65 ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.